BiotechTubeBiotechTube
Home/Monte Rosa Therapeutics/Dr. Brenda Schulman
DB

Dr. Brenda Schulman

Scientific Advisory Board Member

Monte Rosa Therapeutics

Therapeutic Areas

OncologyAutoimmune DiseasesNeurology

Monte Rosa Therapeutics Pipeline

DrugIndicationPhase
MRT-2359MYC-driven solid tumors and lymphomasPhase 1/2
MRT-6160Inflammatory and autoimmune diseasesPreclinical
CDK2 DegraderOncologyPreclinical

Leadership Team at Monte Rosa Therapeutics

DM
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, and Director
DS
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
PV
Philip Vickers, Ph.D.
Head of Research & Development
DA
Dr. Alison L. Hannah, M.D.
Chief Medical Officer
CR
Christopher R. L. Cline, CFA
Chief Financial Officer
DJ
Dr. John Tsai, M.D.
Chair of the Board of Directors
DT
Dr. Thomas G. Wiggans
Director
DT
Dr. Thomas J. Kelly, M.D., Ph.D.
Director
DT
Dr. Thomas C. Reynolds, M.D., Ph.D.
Director
DT
Dr. Thomas B. Neff
Director
View full Monte Rosa Therapeutics profile